June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Interim Results From INJECT: INvestigation of JETREA in Patients With Confirmed Vitreomacular Traction
Author Affiliations & Notes
  • Peter Stalmans
    Dept Ophthalmology UZLeuven, UZLeuven, Leuven, Belgium
  • Franklin Masin
    Alcon Laboratories Inc., Fort Worth, TX
  • Claudio Spera
    Alcon Laboratories Inc., Fort Worth, TX
  • Severine Durier
    Alcon Laboratories Inc., Fort Worth, TX
  • Lawrence Rasouliyan
    ICON Clinical Research, Barcelona, Spain
  • Footnotes
    Commercial Relationships Peter Stalmans, Alcon Laboratories Inc. (C), Alcon Labratories Inc. (C); Franklin Masin, Alcon Laboratories Inc. (E); Claudio Spera, Alon Laboratories Inc. (E); Severine Durier, Alcon Laboratories, Inc. (E); Lawrence Rasouliyan, ICON Clinical Research (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1237. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Stalmans, Franklin Masin, Claudio Spera, Severine Durier, Lawrence Rasouliyan; Interim Results From INJECT: INvestigation of JETREA in Patients With Confirmed Vitreomacular Traction. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1237.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

The safety and clinical efficacy of JETREA (ocriplasmin) have been established in two phase 3 vehicle-controlled clinical studies. However, the long-term effects of ocriplasmin in a real-world setting have not been widely documented in large populations across different countries. The purpose of this study is to characterize baseline characteristics, safety profile, and clinical effectiveness of ocriplasmin in real-world settings across different countries.


Non-interventional, multicenter, prospective study in vitreomacular traction (VMT) patients treated with ocriplasmin. Enrolled patients are followed for 12 months. Frequency and timing of post-injection visits are at the discretion of the treating physician. Patient baseline characteristics collected include age, race, gender, presence and size of macular hole (MH), presence of ERM, and size of vitreomacular adhesion. Safety assessments include ocular symptoms and adverse events.


The interim analysis included 105 patients with available baseline OCT data and at least 28 days of follow-up. The majority of patients were female (62%), white (97%), with a mean age of 72 years (range 46 - 89 years). Most patients presented with VMT without macular hole: 64/105 (61%) with VMT only, and 41/105 (39%) with VMT plus MH. The most frequently reported adverse events were: drug ineffective (n=8), vitreous floaters (n=7), photopsia (n=7), and visual acuity reduced (n=5).


Results from this study provide insights into presenting characteristics of patients with VMT and VMT with MH, who receive ocriplasmin in a real world setting, and will contribute to the further characterization of ocriplasmin efficacy, safety profile, and global treatment patterns.  

Table 1. Demographics and Baseline Characteristics of Study Population.
Table 1. Demographics and Baseline Characteristics of Study Population.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.